Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

250 11 Hybrid Cell Vaccination for Cancer Immune Therapy
gen-specific CTL-mediated protective
tumor immunity. J Exp Med 1996; 183:
283±7.
142 Hu X, Chakraborty NG, Sporn JR,
Kurtzman SH, Ergin MT,
Mukherji B. Enhancement of cytolytic
T lymphocyte precursor frequency in
melanoma patients following immunization
with the MAGE-1 peptide loaded
antigen presenting cell-based vaccine.
Cancer Res 1996; 56: 2479±83.
143 Nestle FO, Alijagic S, Gilliet M,
Sun Y, Grabbe S, Dummer R, Burg G
and Schadendorf D. Vaccination of
melanoma patients with peptide- or tumor
lysate-pulsed dendritic cells. Nat
Med 1998; 4: 328±32.
144 Salio M, Shepherd D, Dunbar PR,
Palmowski M, Murphy K,Wu L,
Cerundolo V. Mature dendritic cells
prime functionally superior melan-Aspecific
CD8 + lymphocytes as compared
with nonprofessional APC. J Immunol
2001; 167: 1188±97.
145 Condon C,Watkins SC, Celluzzi CM,
Thompson K, Falo LD Jr. DNA-based
immunization by in vivo transfection of
dendritic cells. Nat Med 1996; 2: 1122±8.
146 Koido S, Kashiwaba M, Chen D,
Gendler S, Kufe D, Gong J. Induction
of antitumor immunity by vaccination
of dendritic cells transfected with
MUC1 RNA. J Immunol 2000; 165:
5713±9.
147 Van Tendeloo VF, Ponsaerts P, Lardon
F, Nijs G, Lenjou M,Van Broeckhoven
C,Van Bockstaele DR, Berneman
ZN. Highly efficient gene delivery
by mRNA electroporation in human hematopoietic
cells: superiority to lipofection
and passive pulsing of mRNA and
to electroporation of plasmid cDNA for
tumor antigen loading of dendritic
cells. Blood 2001; 98: 49±56.
148 Celluzzi CM, Falo LD Jr. Physical interaction
between dendritic cells and tumor
cells results in an immunogen that
induces protective and therapeutic tumor
rejection. J Immunol 1998; 160:
3081±5.
149 Gong J, Chen D, Kashiwaba M,
Kufe D. Induction of antitumor activity
by immunization with fusions of den-
dritic and carcinoma cells. Nat Med
1997; 3: 558±61.
150 Wang J, Saffold S, Cao X, Krauss J,
Chen W. Eliciting T cell immunity
against poorly immunogenic tumors by
immunization with dendritic cell-tumor
fusion vaccines. J Immunol 1998;
161: 5516±24.
151 Kugler A, Stuhler G,Walden P, Zoller
G, Zobywalski A, Brossart P,
Trefzer U, Ullrich S, Muller CA,
Becker V, Gross AJ, Hemmerlein B,
Kanz L, Muller GA, Ringert RH.
Regression of human metastatic renal
cell carcinoma after vaccination with tumor
cell-dendritic cell hybrids. Nat Med
2000; 6: 332±6.
152 Orentas RJ, Schauer D, Bin Q, Johnson
BD. Electrofusion of a weakly immunogenic
neuroblastoma with dendritic
cells produces a tumor vaccine. Cell
Immunol 2001; 213: 4±13.
153 Kikuchi T, Akasaki Y, Irie M,
Homma S, Abe T, Ohno T. Results of
a phase I clinical trial of vaccination of
glioma patients with fusions of dendritic
and glioma cells. Cancer Immunol
Immunother 2001; 50: 337±44.
154 Homma S, Toda G, Gong J, Kufe D,
Ohno T. Preventive antitumor activity
against hepatocellular carcinoma
(HCC) induced by immunization with
fusions of dendritic cells and HCC cells
in mice. J Gastroenterol 2001; 36: 764±
71.
155 Akasaki Y, Kikuchi T, Homma S,
Abe T, Kofe D, Ohno T. Antitumor effect
of immunizations with fusions of
dendritic and glioma cells in a mouse
brain tumor model. J Immunother 2001;
24: 106±13.
156 Gong J, Apostolopoulos V, Chen D,
Chen H, Koido S, Gendler SJ,
McKenzie IF, Kufe D. Selection and
characterization of MUC1-specific
CD8 + T cells from MUC1 transgenic
mice immunized with dendritic-carcinoma
fusion cells. Immunology 2000;
101: 316±24.
157 Gong J, Nikrui N, Chen D, Koido S,
Wu Z, Tanaka Y, Cannistra S,
Avigan D, Kufe D. Fusions of human
ovarian carcinoma cells with autologous
or allogeneic dendritic cells in-